Maud Majeres Lugand
Biographic Data
| ID | 8958513 |
|---|---|
| NAME | Maud Majeres Lugand |
| GIVEN NAMES | Maud Majeres |
| FAMILY NAME | Lugand |
| SIGNATURE | LUGAND M M |
| AFFILIATIONS | Medicines for Malaria Venture |
| ORCID | 0009-0001-6700-1441 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2026 |
| LATEST PUBLICATION YEAR | 2026 |
| H-INDEX | 0 |
Improving malaria chemoprevention coverage in pregnancy
Sulfadoxine-pyrimethamine (SP) is the only WHO-recommended option for the intermittent preventive treatment of malaria in pregnancy (IPTp). However, coverage is suboptimal, efficacy is limited in areas of high resistance and SP is contraindicated in the first trimester and women living with HIV receiving cotrimoxazole. This study investigated stakeholder perspectives on next-generation IPTp product characteristics and their potential impact on up…
Development of Context-Appropriate Recruitment and Retention Approaches for Pregnant Women in the Safire Clinical Trial Assessing Safety and Efficacy of Artemisinin-Combination Therapies
Pregnant women, particularly those in the first trimester, have been historically excluded from clinical trials, resulting in substantial evidence gaps for the prevention and treatment of malaria in early pregnancy. Despite increasing calls from global health and regulatory bodies to include pregnant women in research, ethical, socio-cultural, and contextual challenges continue to impede their meaningful participation. Formative research is essen…
No prominent works on this page.
Improving malaria chemoprevention coverage in pregnancy
Sulfadoxine-pyrimethamine (SP) is the only WHO-recommended option for the intermittent preventive treatment of malaria in pregnancy (IPTp). However, coverage is suboptimal, efficacy is limited in areas of high resistance and SP is contraindicated in the first trimester and women living with HIV receiving cotrimoxazole. This study investigated stakeholder perspectives on next-generation IPTp product characteristics and their potential impact on up…
Development of Context-Appropriate Recruitment and Retention Approaches for Pregnant Women in the Safire Clinical Trial Assessing Safety and Efficacy of Artemisinin-Combination Therapies
Pregnant women, particularly those in the first trimester, have been historically excluded from clinical trials, resulting in substantial evidence gaps for the prevention and treatment of malaria in early pregnancy. Despite increasing calls from global health and regulatory bodies to include pregnant women in research, ethical, socio-cultural, and contextual challenges continue to impede their meaningful participation. Formative research is essen…
Global Maternal and Child Health (2 works) · Malaria Research and Control (2 works) · Stakeholder (2 works) · Alternative medicine (1 work) · Clinical trial (1 work) · Data collection (1 work) · Dosing (1 work) · Ethics in Clinical Research (1 work) · Focus group (1 work) · Formative assessment (1 work)